Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma
AssigneePureTech LYT, Inc.
InventorsAleksandra FILIPOVIC, Joseph BOLEN, Eric ELENKO
Life of this patent
Estimating the term…
Abstract
Methods for treating an ocular melanoma in a patient. e.g., uveal melanoma, comprising administering to the patient an effective amount of an antibody that binds galectin-9). Also provided herein are methods for identifying a subject as having the ocular melanoma based on the level of Galectin-9) in a biological sample (e.g., a blood sample) from a subject suspected of having the ocular melanoma.
Claims41
A method for treating a solid tumor that expresses galectin-9 in a human subject, comprising administering to the human subject in need thereof an effective amount of a pharmaceutical composition comprising an antibody that binds galectin-9 (anti-galectin-9 antibody),
- wherein the antibody comprises (a) a heavy chain variable region (VH), which comprises a heavy chain complementary determining region 1 (CDR1) set forth as SEQ ID NO:
- 4, a heavy chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 5, and a heavy chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 6 and (b) a light chain variable region (VL), which comprises a light chain CDR1 set forth as SEQ ID NO:
- 1, a light chain CDR2 set forth as SEQ ID NO:
- 2, and a light chain CDR3 set forth as SEQ ID NO:
- 3, and
- wherein the solid tumor is an ocular melanoma.
2-3. (canceled)
(canceled)
19-20. (canceled)
The method of claim 18, wherein the immune checkpoint inhibitor is administered by intravenous infusion or subcutaneous injection. 23 (Previously presented) The method of claim 1, wherein the method further comprises administering a chemotherapy. 24 (Previously presented) The method of claim 23, wherein the chemotherapy comprises an antimetabolite, a microtubule inhibitor, or a combination thereof.
The method of claim 24, wherein the antimetabolite is gemcitabine and/or the microtubule inhibitor is paclitaxel.
(canceled)
(canceled)
33-36. (canceled)
(canceled)
A method for identifying an ocular melanoma patient and optionally treating the patient, the method comprising:
- (i) providing a biological sample of a subject suspected of having an ocular melanoma,
- (ii) measuring the level of galectin-9 in the biological sample, and
- (iii) identifying the subject as having the ocular melanoma or being at risk for the ocular melanoma or based on the level of galectin-9 in the biological sample, wherein an elevated level of galectin-9 in the biological sample of the subject relative to a predetermined reference level indicates that the subject has the ocular melanoma or is at risk for the ocular melanoma.
A method for determining tumor burden or metastatic status in a patient having ocular melanoma, and optionally treating the patient, the method comprising:
- (i) providing a biological sample of a patient having an ocular melanoma,
- (ii) measuring the level of galectin-9 in the biological sample, and
- (iii) determining tumor burden of the patient based on the level of galectin-9 in the blood sample, wherein an elevated level of galectin-9 in the biological sample of the subject relative to a predetermined reference level indicates that the subject has a high tumor burden.
(canceled)
A method for assessing progression of ocular melanoma in a subject and optionally treating the subject, the method comprising:
- (i) providing a first biological sample of a subject having ocular melanoma at a first time point;
- (ii) providing a second biological sample of the subject at a second time point, wherein the second time point is after the first time point;
- (iii) measuring the levels of galectin-9 in the first and second biological samples;
- and
- (iv) determining the progression of ocular melanoma in the subject based on the levels of Gal-9 in the first and second biological samples, wherein an increased level of Gal-9 in the second biological sample relative to the level of Gal-9 in the first biological sample indicates progression of ocular melanoma in the subject.
46-47. (canceled)
A method for determining a response to a treatment in a subject having an ocular melanoma, and optionally modifying the treatment, the method comprising:
- (i) providing multiple biological samples of a ocular melanoma patient who is under a treatment comprising an anti-cancer therapy, wherein the multiple biological samples comprise at least a first biological sample collected before the first dose of the anti-cancer therapy and a second biological sample collected after the first dose of the anti-cancer therapy;
- (ii) measuring the level of galectin-9 in the biological samples;
- and
- (iii) determining the patient's response to the anti-cancer therapy based on the difference between the level of Gal-9 in the first biological sample and the level of Gal-9 in the second biological sample;
- wherein a reduced level of Gal-9 in the second biological sample relative to the first biological sample indicates a response to the anti-cancer therapy in the subject.
49-54. (canceled)
Dependencies are inferred from the claim text.